Drug resistance remains a major problem in combating HIV infection, but a different approach to drug development could be the answer. Current viral inhibitors target the HIV-1 protease function with a competitive mechanism. New research suggests that pharmaceutical companies look at compounds that use an allosteric non-competitive mechanism of inhibition.